DRW Securities’s HCW Biologics HCWB Stock Holding History

DRW Securities’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,880	Closed	-$34.2K	–	1483
2025 Q4	$34.2K	Sell	5,880 -8,026	-58%	-$136K	﹤0.01%	1142
2025 Q3	$309K	Buy	+13,906	New	+$363K	0.01%	825

Other funds holding HCWB

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

DRW Securities's HCWB Position: Q1 2026 in Review

DRW Securities sold out of HCW Biologics (HCWB) in Q1 2026, closing a stake of 5,880 shares — an estimated $34.2K sold.

DRW Securities first reported a position in HCWB in Q3 2025 and held it in 2 quarters. The position peaked at $309K in Q3 2025. 13 funds tracked by Wall St. Rank hold HCWB as of Q1 2026.

DRW Securities reported no remaining HCW Biologics position as of Q1 2026 after selling out during the quarter.
DRW Securities sold 5,880 HCW Biologics shares in Q1 2026, an estimated $34.2K.
DRW Securities first reported a position in HCW Biologics in Q3 2025 and held it in 2 quarters.
DRW Securities's HCW Biologics position peaked at $309K in Q3 2025.
13 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.